Warburg Research set a €115.00 ($136.90) price objective on Merck KGaA (FRA:MRK) in a report published on Wednesday. The brokerage currently has a buy rating on the healthcare company’s stock.

Several other equities research analysts have also recently commented on the company. J P Morgan Chase & Co set a €100.00 ($119.05) target price on Merck KGaA and gave the company a neutral rating in a research note on Tuesday. Nord/LB set a €98.00 ($116.67) target price on Merck KGaA and gave the company a neutral rating in a research note on Friday, December 8th. UBS set a €120.00 ($142.86) target price on Merck KGaA and gave the company a buy rating in a research note on Wednesday, December 6th. Bank of America set a €95.00 ($113.10) target price on Merck KGaA and gave the company a neutral rating in a research note on Wednesday, December 6th. Finally, Morgan Stanley set a €98.00 ($116.67) target price on Merck KGaA and gave the company a neutral rating in a research note on Friday, December 1st. Twelve analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Merck KGaA currently has a consensus rating of Hold and an average price target of €107.81 ($128.34).

Shares of Merck KGaA (MRK) traded down €0.61 ($0.73) on Wednesday, reaching €90.05 ($107.20). 461,183 shares of the company traded hands. Merck KGaA has a 52-week low of €87.33 ($103.96) and a 52-week high of €115.00 ($136.90).

ILLEGAL ACTIVITY NOTICE: “Merck KGaA (MRK) Given a €115.00 Price Target by Warburg Research Analysts” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/14/merck-kgaa-mrk-given-a-115-00-price-target-by-warburg-research-analysts.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Stock Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related stocks with our FREE daily email newsletter.